CRI market research report

Global Neuropathic Pain Market Research Report Forecast to 2027

$4950 – $7250

SKU: MRFR220356 Category: Tag:

Description

Global Neuropathic Pain Market Research Report – Forecast to 2027

Market analysis

Neuropathic Pain Market is anticipated to surpass USD 28,778.20 million by 2027 at a notable CAGR of 6.3% during the review period.
Neuropathic pain is prominently caused by the peripheral nerve disorder. The global market growth is attributed to the introduction of pain management centers along with higher demand for generic drugs.
In Neuropathic Pain Market, diabetes is one of the main sources of expanded neuropathic torment. The subsequent primary driver of neuropathic torment is the destructive infection called disease. According to World Health Organization (WHO) reports, in 2014, there were around 422 million individuals who were experiencing diabetes.
The huge populace is likewise viewed as one of the essential basic drivers of the market. Likewise, better treatment offices, improvement of medical care frameworks, ascend popularity of neuropathic torment and critical ventures by pharma organizations, improvement in nature of medications, and quantities of torment the board frameworks will push the market on a positive course.

Market segmentation

Based on type segment, the global neuropathic pain market has been classified into peripheral neuropathy, post-traumatic neuropathy, post-herpetic neuralgia (PHN), phantom limb pain, entrapment neuropathy, and trigeminal neuralgia. Based on indication, the market is divided into chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and spinal stenosis. In terms of diagnosis, the market is segmented into blood tests, imaging, and physical examination. Based on its treatment, the market is classified into medication type and multimodal therapy. The end-use industries include clinics, hospitals, and research organizations. Based on its distribution channels, the market is divided into online pharmacies and retail pharmacies & drug stores.

Regional analysis

The nations in North America and South America contained an all-out market esteem worth of USD 6,645.09 million in the year 2019. It is anticipated that it will arrive at a CAGR of around 5.6% during the gauge time frame. The rising number of problems connected with neuropathic torment, mechanical turns of events, and ascend in mindfulness are the fundamental elements of the Neuropathic Pain Market development.
The American market is grouped into North America and Latin America. The market of North America is additionally partitioned into the United States of America and Canada.
The neuropathic torment market in Western Europe has been isolated into France, the UK, Germany, Spain, Italy, and other European nations. The market in Asia-Pacific is sectioned into India, Japan, Australia, China, South Korea, and different nations in the Asia-Pacific area. The Market in the Middle East and African district is separated into the Middle East and Africa.

Major players

Sanofi S.A. (France), Abbott Laboratories (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), and Depomed Inc. (U.S.), Eli Lilly and Company (U.S.), Astellas Pharma Inc. (Tokyo), Biogen Inc. (U.S.), Baxter Healthcare Corporation (U.S.), Pfizer, Inc. (U.S.), among others, are some of the major players in the global neuropathic pain market.

Additional information

Publisher

Geography Covered

Date Published

Pages

Format

Table of Contents

TABLE OF CONTENT 1 EXECUTIVE SUMMARY 2 MARKET INTRODUCTION 2.1 DEFINITION 22 2.2 SCOPE OF THE STUDY 22 2.3 RESEARCH OBJECTIVE 22 2.4 MARKET STRUCTURE 23 2.5 ASSUMPTIONS & LIMITATIONS 24 3 RESEARCH METHODOLOGY 3.1 DATA MINING 25 3.2 SECONDARY RESEARCH 26 3.3 PRIMARY RESEARCH 27 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 28 3.5 FORECASTING TECHNIQUES 29 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 30 3.6.1 BOTTOM-UP APPROACH 31 3.6.2 TOP-DOWN APPROACH 31 3.7 DATA TRIANGULATION 32 3.8 VALIDATION 32 4 MARKET DYNAMICS 4.1 OVERVIEW 33 4.2 DRIVERS 34 4.2.1 RISING PREVALENCE OF DIABETIC NEUROPATHY 34 4.2.2 INCREASING HEALTHCARE EXPENDITURE 34 4.2.3 GROWING NUMBER OF INCIDENCE OF TRAUMA FROM INJURY AND OTHER CONDITIONS 35 4.3 RESTRAINTS 36 4.3.1 INCREASING COUNTERFEIT DRUGS & SIDE EFFECTS OF THE THERAPEUTIC TREATMENT 36 4.3.2 LACK OF AWARENESS ABOUT THE NEUROLOGICAL CONDITION 37 4.4 OPPORTUNITIES 38 4.4.1 NEW PRODUCT LAUNCH IN DEVELOPING REGIONS 38 5 MARKET FACTOR ANALYSIS 5.1 VALUE CHAIN ANALYSIS 39 5.1.1 R&D 40 5.1.2 MANUFACTURING 40 5.1.3 DISTRIBUTION AND SALES 40 5.1.4 POST-SALES MONITORING 40 5.2 PORTER’S FIVE FORCES MODEL 41 5.2.1 BARGAINING POWER OF SUPPLIERS 42 5.2.2 BARGAINING POWER OF BUYERS 42 5.2.3 THREAT OF NEW ENTRANTS 42 5.2.4 THREAT OF SUBSTITUTES 42 5.2.5 INTENSITY OF RIVALRY 42 5.3 IMPACT ANALYSIS OF COVID-19 ON THE GLOBAL NEUROPATHIC PAIN MARKET 43 5.3.1 OVERVIEW 43 5.3.2 IMPACT ON ONGOING TREATMENTS AND DELAYED AVAILABILITY DUE TO DEFERMENT 43 5.3.3 IMPACT ON NUMBER OF PATIENTS 44 6 GLOBAL NEUROPATHIC PAIN MARKET, BY TYPE 6.1 OVERVIEW 45 6.2 PERIPHERAL NEUROPATHY 47 6.3 ENTRAPMENT NEUROPATHY 47 6.4 TRIGEMINAL NEURALGIA 48 6.5 PHANTOM LIMB PAIN 48 6.6 POST HERPETIC NEURALGIA (PHN) 49 6.7 POST TRAUMATIC NEUROPATHY 49 7 GLOBAL NEUROPATHIC PAIN MARKET, BY INDICATION 7.1 OVERVIEW 50 7.2 DIABETIC NEUROPATHY 52 7.3 SPINAL STENOSIS 52 7.4 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY 53 7.5 OTHERS 53 8 GLOBAL NEUROPATHIC PAIN MARKET, BY DIAGNOSIS 8.1 OVERVIEW 54 8.2 IMAGING 55 8.3 BLOOD TESTS 56 8.4 PHYSICAL EXAMINATION 56 9 GLOBAL NEUROPATHIC PAIN MARKET, BY TREATMENT 9.1 OVERVIEW 57 9.2 MEDICATION 58 9.3 MULTIMODAL THERAPY 60 10 GLOBAL NEUROPATHIC PAIN SMARKET, BY DISTRIBUTION CHANNEL 10.1 OVERVIEW 61 10.2 RETAIL PHARMACIES & DRUG STORES 62 10.3 ONLINE PHARMACIES 62 11 GLOBAL NEUROPATHIC PAIN MARKET, BY END USER 11.1 OVERVIEW 63 11.2 HOSPITALS 64 11.3 CLINICS 64 11.4 RESEARCH ORGANIZATIONS 65 12 GLOBAL NEUROPATHIC PAIN MARKET, BY REGION 12.1 OVERVIEW 66 12.2 AMERICAS 67 12.2.1 NORTH AMERICA 72 12.2.1.1 US 77 12.2.1.2 CANADA 81 12.2.2 LATIN AMERICA 85 12.3 EUROPE 90 12.3.1 WESTERN EUROPE 95 12.3.1.1 GERMANY 100 12.3.1.2 UK 104 12.3.1.3 FRANCE 108 12.3.1.4 ITALY 112 12.3.1.5 SPAIN 116 12.3.1.6 REST OF WESTERN EUROPE 120 12.3.2 EASTERN EUROPE 124 12.4 ASIA-PACIFIC 129 12.4.1 CHINA 134 12.4.2 INDIA 138 12.4.3 JAPAN 142 12.4.4 SOUTH KOREA 146 12.4.5 AUSTRALIA 150 12.4.6 REST OF ASIA-PACIFIC 154 12.5 MIDDLE EAST & AFRICA 159 12.5.1 MIDDLE EAST 164 12.5.2 AFRICA 168 13 COMPETITIVE LANDSCAPE 13.1 OVERVIEW 173 13.2 COMPETITIVE BENCHMARKING 174 13.3 GLOBAL NEUROPATHIC PAIN MARKET: COMPANY RANKING, 2020 175 13.4 MAJOR GROWTH STRATEGY IN THE GLOBAL NEUROPATHIC PAIN MARKET 175 13.5 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS 176 13.6 COMPETITIVE BENCHMARKING: GLOBAL NEUROPATHIC PAIN MARKET 176 13.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 177 13.7.1 PRODUCT APPROVALS AND LAUNCHES 177 13.7.2 ACQUISITIONS 177 13.8 FINANCIAL MATRIX 178 14 COMPANY PROFILES 14.1 ABBOTT 179 14.1.1 COMPANY OVERVIEW 179 14.1.2 FINANCIAL OVERVIEW 180 14.1.3 PRODUCTS/SERVICES OFFERED 180 14.1.4 KEY DEVELOPMENTS 181 14.1.5 SWOT ANALYSIS 182 14.1.6 KEY STRATEGIES 182 14.2 PFIZER 183 14.2.1 COMPANY OVERVIEW 183 14.2.2 FINANCIAL OVERVIEW 183 14.2.3 PRODUCTS/SERVICES OFFERED 184 14.2.4 KEY DEVELOPMENTS 184 14.2.5 SWOT ANALYSIS 184 14.2.6 KEY STRATEGIES 184 14.3 JOHNSON & JOHNSON SERVICES, INC. 185 14.3.1 COMPANY OVERVIEW 185 14.3.2 FINANCIAL OVERVIEW 186 14.3.3 PRODUCTS/SERVICES OFFERED 186 14.3.4 KEY DEVELOPMENTS 186 14.3.5 SWOT ANALYSIS 187 14.3.6 KEY STRATEGIES 187 14.4 BAXTER INTERNATIONAL 188 14.4.1 COMPANY OVERVIEW 188 14.4.2 FINANCIAL OVERVIEW 188 14.4.3 PRODUCTS/SERVICES OFFERED 189 14.4.4 KEY DEVELOPMENTS 189 14.4.5 SWOT ANALYSIS 189 14.4.6 KEY STRATEGIES 190 14.5 ELI LILY AND COMPANY 190 14.5.1 COMPANY OVERVIEW 190 14.5.2 FINANCIAL OVERVIEW 191 14.5.3 PRODUCTS/SERVICES OFFERED 191 14.5.4 KEY DEVELOPMENTS 191 14.5.5 SWOT ANALYSIS 192 14.5.6 KEY STRATEGIES 192 14.6 GLAXOSMITHKLINE PLC 193 14.6.1 COMPANY OVERVIEW 193 14.6.2 FINANCIAL OVERVIEW 193 14.6.3 PRODUCTS/SERVICES OFFERED 194 14.6.4 KEY DEVELOPMENTS 194 14.6.5 SWOT ANALYSIS 194 14.6.6 KEY STRATEGIES 195 14.7 SANOFI 195 14.7.1 COMPANY OVERVIEW 195 14.7.2 FINANCIAL OVERVIEW 196 14.7.3 PRODUCTS/SERVICES OFFERED 196 14.7.4 KEY DEVELOPMENTS 197 14.7.5 SWOT ANALYSIS 197 14.7.6 KEY STRATEGIES 197 14.8 ASTRAZENECA 198 14.8.1 COMPANY OVERVIEW 198 14.8.2 FINANCIAL OVERVIEW 198 14.8.3 PRODUCTS/SERVICES OFFERED 199 14.8.4 KEY DEVELOPMENTS 199 14.8.5 SWOT ANALYSIS 199 14.8.6 KEY STRATEGIES 199 14.9 DEPOMED INC. (ASSERTIO THERAPEUTICS, INC) 200 14.9.1 COMPANY OVERVIEW 200 14.9.2 FINANCIAL OVERVIEW 200 14.9.3 PRODUCTS/SERVICES OFFERED 200 14.9.4 KEY DEVELOPMENTS 201 14.9.5 SWOT ANALYSIS 201 14.9.6 KEY STRATEGIES 202 14.10 BIOGEN, INC. 202 14.10.1 COMPANY OVERVIEW 202 14.10.2 FINANCIAL OVERVIEW 202 14.10.3 PRODUCTS/SERVICES OFFERED 203 14.10.4 KEY DEVELOPMENTS 203 14.10.5 SWOT ANALYSIS 203 14.10.6 KEY STRATEGIES 203 14.11 ASTELLAS PHARMA LTD. 204 14.11.1 COMPANY OVERVIEW 204 14.11.2 FINANCIAL OVERVIEW 204 14.11.3 PRODUCTS/SERVICES OFFERED 205 14.11.4 KEY DEVELOPMENTS 205 14.11.5 SWOT ANALYSIS 205 14.11.6 KEY STRATEGIES 206 15 APPENDIX 15.1 REFERENCES 207 15.2 RELATED REPORTS 207

Companies Mentioned

Sanofi S.A. (France), Abbott Laboratories (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), and Depomed Inc. (U.S.), Eli Lilly and Company (U.S.), Astellas Pharma Inc. (Tokyo), Biogen Inc. (U.S.), Baxter Healthcare Corporation (U.S.), Pfizer, Inc. (U.S.)

Reviews

There are no reviews yet.

Be the first to review “Global Neuropathic Pain Market Research Report Forecast to 2027”

Related products